conversation on covid19
Answers
Answer:
Coronavirus: A new type of vaccine using RNA could help defeat COVID-19
A century ago, on July 26, 1916, a viral disease swept through New York. Within 24 hours, new cases of polio increased by more than 68%. The outbreak killed more than 2,000 people in New York City alone. Across the United States, polio took the lives of about 6,000 people in 1916, leaving thousands more paralyzed.
Although scientists had already identified the polio virus, it took 50 more years to develop a vaccine. That vaccine eradicated polio in the U.S. in less than a decade. Vaccines are one of the most effective modern disease-fighting tools.
As of this writing, the fast-spreading COVID-19 has already infected almost half a million worldwide, and has killed over 22,000 patients. There is an urgent need for a vaccine to prevent it from infecting and killing millions more. But traditional vaccine development takes, on average, 16 years.
So how can scientists quickly develop a vaccine for SARS-CoV-2?
As immunologists, we are trying to expedite development of vaccines and antibody therapeutics. We’re currently developing novel vaccine candidates for Zika, and have successfully developed a potential protective antibody-based treatment – in 90 days – to stop that viral disease. Fast-track “sprints” like these are part of the Pandemic Protection Platform Program run by the Defense Advanced Research Agency of the U.S. Department of Defense to help us identify and deploy protective antibody treatments against viral outbreaks, such as SARS-CoV-2. Now other colleagues of ours are working on expediting a new type of vaccine for COVID-19.
As millions of workers around the globe are thrust suddenly into remote work situations, the experience of Deloitte Consulting Global CMO David Redhill and his colleagues in Australia reveals a huge, and perhaps unexpected, upside.
Many companies have decided or will soon decide to perform most work virtually in response to the spread of COVID-19, shining a spotlight on the need for corporate resilience and the ability to embrace virtual collaboration tools and practices. A practical approach can help companies adapt and progress in this dynamic environment.
The virus that brought parts of China and much of Italy to a standstill continues to spread to other parts of the world, extending business continuity challenges and supply chain disruptions into new geographic areas. As organizations manage and adapt, they may need to consider a number of talent, IT, succession, and cash flow initiatives to work through uncertainty and volatility.
In a volatile and uncertain environment, digital capabilities may enable organizations to be proactive and agile in response to emerging disruptions, augmenting their ability to be resilient.
CFOs can help adapt supply chains and corporate spending plans disrupted by the COVID-19 coronavirus outbreak by working with supply chain leaders to identify, assess and implement effective options. Consider several actions that can improve supply chain resiliency and strategic agility now and longer-term.